| Identification | Back Directory | [Name]
Seocalcitol | [CAS]
134404-52-7 | [Synonyms]
Seocalcitol
(1R,3S,5Z)-5-((2E)-((1R,3aS,7aR)-1-((1R,2E,4E)-6-Ethyl-6-hydroxy-1-methyl-2,4-octadienyl)octahydro-7a-methyl-4H-inden-4-ylidene)ethylidene)-4-methylene-1,3-cyclohexanediol
(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(1R,2E,4E)-6-Ethyl-6-hydroxy-1-methyl-2,4-octadien-1-yl]-octahydro-7α-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-1,3-cyclohexanediol
1,3-Cyclohexanediol, 5-[(2E)-2-[(1R,3aS,7aR)-1-[(1R,2E,4E)-6-ethyl-6-hydroxy-1-methyl-2,4-octadien-1-yl]octahydro-7a-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-, (1R,3S,5Z)-
EB 1089,(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(1R,2E,4E)-6-Ethyl-6-hydroxy-1-methyl-2,4-octadien-1-yl]-octahydro-7α-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-1,3-cyclohexanediol | [Molecular Formula]
C30H46O3 | [MDL Number]
MFCD00871599 | [MOL File]
134404-52-7.mol | [Molecular Weight]
454.68 |
| Chemical Properties | Back Directory | [Melting point ]
123-125° | [Boiling point ]
608.5±55.0 °C(Predicted) | [density ]
1.06±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
solid | [pka]
14.29±0.29(Predicted) | [color ]
White | [InChIKey]
LVLLALCJVJNGQQ-QMWUBLQMSA-N | [SMILES]
C[C@@]12[C@](CC[C@]2([H])[C@@H](/C=C/C=C/C(CC)(O)CC)C)([H])/C(CCC1)=C/C=C3C[C@@H](O)C[C@H](O)C/3=C |
| Hazard Information | Back Directory | [Description]
EB 1089 is a synthetic vitamin D analog that is 50-200 times more potent than calcitriol at inhibiting cell proliferation and differentiation, yet displays reduced calcemic activity compared to that of calcitriol. It has been shown to promote tumor regression in vitro by inducing apoptosis. | [Uses]
EB 1089 is an analogue of Calcitriol (C144500), which is a biologically active form of Vitamin D3 (1). It can be used in androgen receptor-targeted therapy research for breast cancer (2). EB 1089 exhibits anti-cancer properties. | [in vivo]
Seocalcitol (EB1089), a synthetic vitamin D analog, exhibits reduced hypercalcemic activity relative to 1,25(OH)2VD3. In another study, long-term intraperitoneal (IP) administration of Seocalcitol at a dose of 0.5 μg/kg body weight every other day in C3H/Sy mice exertes a very strong inhibitory effect on hepatocellular carcinoma (HCC) development[4]. Seocalcitol (EB 1089) is administered daily to postnatal rats from 4 to 12 days of age (P4 to P12) by intraperitoneal injection at either 0.38 or 1.25 μg/kg body weight (BW)/day. Only the highest dose of Seocalcitol (1.25 μg/kg BW) causes a significant reduction in weight gain when administered alone or in conjunction with Dexamethasone, all-trans retinoic acid (RA), or retinoic acid[5]. | [References]
[1] C M HANSEN. Seocalcitol (EB 1089): a vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation.[J]. Current pharmaceutical design, 2000, 6 7: 803-828. DOI: 10.2174/1381612003400371
[2] S Y JAMES. EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro.[J]. British Journal of Pharmacology, 1998, 125 5: 953-962. DOI: 10.1038/sj.bjp.0702103 |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Telephone: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0_EN.htm |
| Company Name: |
LETOPHARM LIMITED
|
| Telephone: |
+86-21-5821 5861 |
| Website: |
www.letopharm.com |
|